R&D, manufacturing and sales of innovative biologic therapeutics to treat human diseases; marketed products include Voriconazole and an EGF franchise, with two new drugs (rhExtendin‑4 and rhPTH 1‑34) having completed clinical trials. Targets patients in China and biopharma partners by providing GMP-manufactured, cost‑effective treatments and partnership-focused development.